NASDAQ:VCYT Veracyte (VCYT) Stock Price, News & Analysis → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free VCYT Stock Alerts $19.83 -0.02 (-0.10%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$19.81▼$20.7050-Day Range$18.86▼$25.5352-Week Range$18.61▼$30.52Volume563,798 shsAverage Volume619,509 shsMarket Capitalization$1.49 billionP/E RatioN/ADividend YieldN/APrice Target$29.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Veracyte alerts: Email Address Veracyte MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.60 Rating ScoreUpside/Downside46.2% Upside$29.00 Price TargetShort InterestBearish4.85% of Shares Sold ShortDividend StrengthN/ASustainability-1.02Upright™ Environmental ScoreNews Sentiment0.11Based on 6 Articles This WeekInsider TradingSelling Shares$216,500 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.29) to $0.01 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.50 out of 5 starsMedical Sector265th out of 909 stocksMedical Laboratories Industry7th out of 19 stocks 3.3 Analyst's Opinion Consensus RatingVeracyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 4 buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageVeracyte has only been the subject of 4 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.85% of the outstanding shares of Veracyte have been sold short.Short Interest Ratio / Days to CoverVeracyte has a short interest ratio ("days to cover") of 5.7.Change versus previous monthShort interest in Veracyte has recently increased by 32.85%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldVeracyte does not currently pay a dividend.Dividend GrowthVeracyte does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreVeracyte has received a 67.11% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Diagnostic test kits", "Management consulting for the pharmaceutical industry", and "DNA sequencers" products. See details.Environmental SustainabilityThe Environmental Impact score for Veracyte is -1.02. Previous Next 1.7 News and Social Media Coverage News SentimentVeracyte has a news sentiment score of 0.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Veracyte this week, compared to 3 articles on an average week. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Veracyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $216,500.00 in company stock.Percentage Held by InsidersOnly 2.60% of the stock of Veracyte is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Veracyte are expected to grow in the coming year, from ($0.29) to $0.01 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Veracyte is -19.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Veracyte is -19.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVeracyte has a P/B Ratio of 1.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Veracyte Stock (NASDAQ:VCYT)Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.Read More VCYT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VCYT Stock News HeadlinesApril 3, 2024 | insidertrades.comVeracyte, Inc. (NASDAQ:VCYT) Director Karin Eastham Sells 10,000 SharesApril 22, 2024 | businesswire.comVeracyte to Release First Quarter 2024 Financial Results on May 7, 2024April 24, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 22, 2024 | finance.yahoo.comNew Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active SurveillanceApril 22, 2024 | businesswire.comNew Study Shows Veracyte's Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active SurveillanceApril 20, 2024 | americanbankingnews.comVeracyte, Inc. (NASDAQ:VCYT) Given Consensus Rating of "Moderate Buy" by BrokeragesApril 17, 2024 | finance.yahoo.comVeracyte, Inc. (VCYT)April 16, 2024 | businesswire.comVeracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024April 24, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 16, 2024 | americanbankingnews.comVeracyte (NASDAQ:VCYT) Price Target Lowered to $28.00 at The Goldman Sachs GroupApril 16, 2024 | americanbankingnews.comVeracyte (NASDAQ:VCYT) Hits New 1-Year Low on Analyst DowngradeApril 15, 2024 | americanbankingnews.comVeracyte, Inc. (NASDAQ:VCYT) Short Interest Up 32.8% in MarchApril 2, 2024 | finance.yahoo.comWhat Makes Veracyte (VCYT) a Lucrative Investment?March 16, 2024 | finance.yahoo.comVCYT Apr 2024 30.000 callFebruary 27, 2024 | businesswire.comVeracyte's Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN GuidelinesFebruary 26, 2024 | investorplace.com7 Under-the-Radar Biotech Stocks Gearing Up for LiftoffFebruary 26, 2024 | markets.businessinsider.comVeracyte’s Strategic Growth and Market Positioning Inspire Positive Analyst OutlookFebruary 24, 2024 | finance.yahoo.comVeracyte Full Year 2023 Earnings: Revenues Beat Expectations, EPS LagsFebruary 23, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Veracyte (VCYT), Irhythm Technologies (IRTC)February 23, 2024 | finance.yahoo.comVeracyte, Inc. (NASDAQ:VCYT) Q4 2023 Earnings Call TranscriptFebruary 22, 2024 | benzinga.comRecap: Veracyte Q4 EarningsFebruary 22, 2024 | finance.yahoo.comVeracyte Inc (VCYT) Reports 22% Revenue Growth in 2023, Maintains Positive Cash Flow OutlookFebruary 22, 2024 | seekingalpha.comVeracyte, Inc. 2023 Q4 - Results - Earnings Call PresentationFebruary 22, 2024 | businesswire.comVeracyte Announces Fourth Quarter and Full-Year 2023 Financial ResultsFebruary 21, 2024 | finance.yahoo.comVeracyte to Participate in the Raymond James 45th Annual Institutional Investors ConferenceFebruary 21, 2024 | businesswire.comVeracyte to Participate in the Raymond James 45th Annual Institutional Investors ConferenceFebruary 19, 2024 | finance.yahoo.comVCYT Mar 2024 35.000 putSee More Headlines Receive VCYT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Veracyte and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today4/23/2024Next Earnings (Confirmed)5/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryN/A Current SymbolNASDAQ:VCYT CUSIPN/A CIK1384101 Webwww.veracyte.com Phone(650) 243-6300Fax650-243-6301Employees815Year Founded2006Price Target and Rating Average Stock Price Target$29.00 High Stock Price Target$34.00 Low Stock Price Target$21.00 Potential Upside/Downside+46.2%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-74,400,000.00 Net Margins-20.61% Pretax Margin-21.22% Return on Equity-2.02% Return on Assets-1.89% Debt Debt-to-Equity RatioN/A Current Ratio4.66 Quick Ratio4.40 Sales & Book Value Annual Sales$361.05 million Price / Sales4.12 Cash Flow$0.09 per share Price / Cash Flow209.56 Book Value$14.30 per share Price / Book1.39Miscellaneous Outstanding Shares75,070,000Free Float73,116,000Market Cap$1.49 billion OptionableOptionable Beta1.62 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Marc A. Stapley (Age 54)CEO & Director Comp: $1.25MMs. Rebecca Chambers (Age 45)Executive VP & CFO Comp: $772.41kMs. Annie McGuire (Age 43)Executive VP, General Counsel & Chief People Officer Comp: $633.65kMr. Jonathan Wygant (Age 53)VP & Chief Accounting Officer Mr. Steven FrenchSenior VP & Chief Information OfficerDr. Phillip G. Febbo M.D. (Age 58)Chief Scientific & Medical Officer Ms. Karen PossematoSenior Vice President of Corporate Marketing, Communications & Commercial OperationsMr. Robert Brainin (Age 53)Executive VP & Chief Business Officer Dr. John Leite Ph.D.Chief Commercial Officer for CLIA BusinessMs. Corinne DananSenior Vice PresidentMore ExecutivesKey CompetitorsViridian TherapeuticsNASDAQ:VRDNGuardant HealthNASDAQ:GHFulgent GeneticsNASDAQ:FLGTCastle BiosciencesNASDAQ:CSTLCelcuityNASDAQ:CELCView All CompetitorsInsiders & InstitutionsEFG Asset Management Americas Corp.Sold 3,273 shares on 4/22/2024Ownership: 0.012%Sumitomo Mitsui Trust Holdings Inc.Bought 242,760 shares on 4/19/2024Ownership: 4.459%AMI Asset Management CorpBought 13,620 shares on 4/19/2024Ownership: 0.271%Diversified Trust CoBought 8,050 shares on 4/18/2024Ownership: 0.030%Allspring Global Investments Holdings LLCBought 778 shares on 4/18/2024Ownership: 0.012%View All Insider TransactionsView All Institutional Transactions VCYT Stock Analysis - Frequently Asked Questions Should I buy or sell Veracyte stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last twelve months. There are currently 1 sell rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" VCYT shares. View VCYT analyst ratings or view top-rated stocks. What is Veracyte's stock price target for 2024? 5 Wall Street analysts have issued 12-month price targets for Veracyte's shares. Their VCYT share price targets range from $21.00 to $34.00. On average, they anticipate the company's share price to reach $29.00 in the next twelve months. This suggests a possible upside of 46.2% from the stock's current price. View analysts price targets for VCYT or view top-rated stocks among Wall Street analysts. How have VCYT shares performed in 2024? Veracyte's stock was trading at $27.51 at the beginning of 2024. Since then, VCYT stock has decreased by 27.9% and is now trading at $19.83. View the best growth stocks for 2024 here. Are investors shorting Veracyte? Veracyte saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 3,640,000 shares, an increase of 32.8% from the March 15th total of 2,740,000 shares. Based on an average daily volume of 633,600 shares, the days-to-cover ratio is currently 5.7 days. View Veracyte's Short Interest. When is Veracyte's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024. View our VCYT earnings forecast. How can I listen to Veracyte's earnings call? Veracyte will be holding an earnings conference call on Tuesday, May 7th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were Veracyte's earnings last quarter? Veracyte, Inc. (NASDAQ:VCYT) released its quarterly earnings results on Thursday, February, 22nd. The biotechnology company reported ($0.04) earnings per share for the quarter, topping analysts' consensus estimates of ($0.07) by $0.03. The biotechnology company earned $98.20 million during the quarter, compared to analyst estimates of $95.49 million. Veracyte had a negative net margin of 20.61% and a negative trailing twelve-month return on equity of 2.02%. What ETFs hold Veracyte's stock? ETFs with the largest weight of Veracyte (NASDAQ:VCYT) stock in their portfolio include Global X Telemedicine & Digital Health ETF (EDOC), Global X Genomics & Biotechnology ETF (GNOM), ARK Genomic Revolution ETF (ARKG), Invesco Biotechnology & Genome ETF (PBE), ARK Innovation ETF (ARKK), WisdomTree BioRevolution Fund (WDNA) and ARK Next Generation Internation ETF (ARKW).First Trust Nasdaq Lux Digital Health Solutions ETF (EKG). What guidance has Veracyte issued on next quarter's earnings? Veracyte updated its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $394.0 million-$402.0 million, compared to the consensus revenue estimate of $393.3 million. What other stocks do shareholders of Veracyte own? Based on aggregate information from My MarketBeat watchlists, some companies that other Veracyte investors own include Hawkins (HWKN), Invitae (NVTA), AbbVie (ABBV), Xtrackers California Municipal Bond ETF (CA), CRISPR Therapeutics (CRSP), Advanced Micro Devices (AMD), Editas Medicine (EDIT), NVIDIA (NVDA), Exelixis (EXEL) and NeoGenomics (NEO). Who are Veracyte's major shareholders? Veracyte's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (4.46%), AMI Asset Management Corp (0.27%), Diversified Trust Co (0.03%), Los Angeles Capital Management LLC (0.03%), Artemis Investment Management LLP (0.01%) and Allspring Global Investments Holdings LLC (0.01%). Insiders that own company stock include Bonnie H Anderson, Evan/ Fa Jones, Giulia C Kennedy, Giulia C Kennedy, Jens Holstein, John L Bishop, Karin Eastham, Marc Stapley and Muna Bhanji. View institutional ownership trends. How do I buy shares of Veracyte? Shares of VCYT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Veracyte have any subsidiaries? The following companies are subsidiares of Veracyte: Allegro Diagnostics, Decipher Biosciences Inc., Decipher Corp., Delight Merger Sub II LLC, HalioDx Inc., Veracyte Global B.V., Veracyte International Corp., and Veracyte SAS.Read More This page (NASDAQ:VCYT) was last updated on 4/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencySHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsThe #1 Crypto for 2024InvestorPlaceMan Who Predicted 2008: “This Will be Worse.”AltimetryBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Veracyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
